

Date:- 9/12/2021

NIFTY WRAP UP & FORECASTING

The BSE sensex closed the shop at 58,807 **UP** by 157 points and the Nifty close the day at 17,505 by **adding 35** points.

On the Upside: ITC, IT, ASIANPAINT, UPL

On the downside- HDFC Bank, Titan, Nestleindia, SBI life.

Tech View:- Today's session The BSE benchmark, the Sensex, opened 180 points higher at 58,831, and soon jumped 224 points, or 0.4 per cent, at 58,890 levels in early deals. We have witnessed profit booking soon after that which drag to a low of 58,341 down 549 points from the day's high. The Sensex eventually ended at 58,807, up 157 points, Where; The NSE Nifty gyrated between a high of 17,543 and a low of 17,380 and finally settled 47 points higher at 17,517.

Nifty have formed a Bearish Hammer sort of candle on daily chart, Which clearly shows buying was seen from the bottom so going forward strong resistance zone will be 17600-17700 and 17400-17300 will act as a support.

European & USA markets: @ IST 4:10 European markets were trading at **Negative** note. Where the Germany's DAX trading **Negative** by 0.29 %, Other hand France's CAC40 index running **Negative** by 0.02% **where**, England's FTSE100 index **Negative** by 0.11%.

Where; **wall street @ IST 04:10** The DOW future contract trading **Negative** 133 points, S&P 500 Future trading **Negative** 16 points, Where; Nasdaq100 future **Negative** 67 points.

Global News Analysis:

GENEVA - The World Health Organization's (WHO) vaccine advisory panel recommends that people who are immunocompromised or received an inactivated vaccine should receive a booster dose of a COVID-19 shot, the head of the panel said on Thursday.

LONDON - The dollar edged higher Thursday, but remained on the back foot as risk appetite remained strong on positive news surrounding the likely economic damage caused by the Omicron Covid variant.

LONDON - Oil prices eased after early gains on Thursday after measures by some governments to slow the spread of the Omicron coronavirus variant, though losses were capped by positive comments from vaccine makers about the efficacy of their jabs.